WHO panel is reviewing whether COVID vaccines need updating, as agency monitors 7 omicron subvariants
In the latest sign that the coronavirus pandemic is not yet over, the World Health Organization said this week that a panel of experts is reviewing whether COVID vaccines need to be updated.
“However, there has been continuous and substantial evolution of SARS-CoV-2 since the virus emerged, posing challenges to the ongoing public health response, including ensuring that vaccines continue to provide protection,” the authors wrote. The WHO is now monitoring seven omicron subvariants, according to its weekly epidemiological update, up from four a week ago. The seven are BF.7, BQ.1, BA.2.75, CH.1.1, XBB, XBB.1.5 and XBF.
As usual, it cautioned that the numbers may be distorted by a pullback in testing and surveillance and noted that the numbers are higher in prevalance surveys. Cases are currently rising in 17 states and are flat in Oregon and South Dakota. Georgia leads with a 75% increase from two weeks ago. On a per capita basis, Delaware leads with 18 cases per 100,000 residents, the tracker shows.• Moderna’s MRNA stock took a tumble on Thursday when the vaccine maker posted fourth-quarter earnings that fell short of estimates, amid a steep decline in sales of its COVID vaccine, Spikevax — which is the company’s sole product to have won regulatory approval.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna forecasts COVID sales decline as costs rise, shares fallModerna Inc on Thursday forecast declining COVID-19 vaccine sales and rising costs for 2023, raising concerns the U.S. biotech company could post a loss this year, and its shares fell 7%.
Read more »
Stocks making the biggest moves after hours: Nvidia, Etsy, Lucid, Bumble, Moderna and moreStocks making the biggest moves after hours: Etsy, Lucid, Bumble, Moderna and more
Read more »
Moderna's combination skin cancer therapy receives FDA's breakthrough tagModerna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.
Read more »
Moderna's 2022 Windfall a 'Scandalous' Result of Pandemic Profiteering, Campaigners SayOne advocate said Moderna's windfall was a 'direct result of the company’s refusal to share vaccine technology with the Global South, even when it was clear that global shortages would be deadly.'
Read more »
Sliding vaccine sales, new costs, squeeze Moderna 4Q profitModerna’s fourth-quarter profit tumbled 70% as COVID-19 vaccine sales fell and the drugmaker caught up on a royalty payment.
Read more »
Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first halfModerna Inc. said Thursday it had net income of $1.465 billion, or $3.61 a share, in the fourth quarter, down from $4.868 billion, or $11.29 a share, in the...
Read more »